AB Science announces the successful completion of a EUR 1.925 million private placement

Core Viewpoint - AB Science S.A. successfully completed a private placement raising EUR 1.925 million to finance ongoing activities, particularly the clinical development of the AB8939 program [1][3]. Use of Proceeds - The net proceeds from the private placement will be utilized to support the clinical development of the AB8939 program and strengthen the company's cash position to meet financing needs for 2025 and beyond [3]. Private Placement Details - The private placement involved the issuance of 1,645,302 new ordinary shares, each with an attached share warrant (BSA), without preferential subscription rights [4][5]. - The issue price of one ABSA is EUR 1.17, reflecting a 24.36% discount to the volume-weighted average price (VWAP) of AB Science shares over the three trading days prior to the pricing [6][7]. Shareholder Impact - Post-placement, the new shares will represent approximately 2.47% of the company's share capital on a non-diluted basis before the placement and 2.41% after [5]. - Existing shareholders who do not participate in the private placement will experience a dilution of their shareholding [12][22]. Trading and Admission - The new shares are expected to be admitted to trading on Euronext Paris on July 10, 2025, and will be assimilated to existing shares [13]. Lock-up Commitments - The company has agreed to a 45-day lock-up period for the investors and a 90-day lock-up for its directors and officers following the settlement and delivery of the private placement [17].